This award will establish an exciting five-year multidisciplinary research programme at the forefront of research in the development of novel therapeutic agents for the treatment of Human African Trypanosomiasis (HAT) inspired by nature. The acetogenin family of natural products provide a molecular blueprint for the design of novel trypanocidal drugs. Such an approach to the discovery of HAT inhibitors has not been implemented despite the widespread use of Annonaceae plant family of trees, shrubs and vines in traditional medicine across sub-Saharan Africa. The challenge is to combine our expertise in organic synthesis and molecular parasitology within the Biomedical Science Research Complex to bring about a step change in drug discovery for this neglected disease.
Friday, 26 October 2012
Leverhulme Research Leadership Award for drug discovery research in neglected diseases
Dr Gordon Florence, Royal Society University Research Fellow in the School of Chemistry, received a prestigious Research Leadership Award from The Leverhulme Trust.
This award will establish an exciting five-year multidisciplinary research programme at the forefront of research in the development of novel therapeutic agents for the treatment of Human African Trypanosomiasis (HAT) inspired by nature. The acetogenin family of natural products provide a molecular blueprint for the design of novel trypanocidal drugs. Such an approach to the discovery of HAT inhibitors has not been implemented despite the widespread use of Annonaceae plant family of trees, shrubs and vines in traditional medicine across sub-Saharan Africa. The challenge is to combine our expertise in organic synthesis and molecular parasitology within the Biomedical Science Research Complex to bring about a step change in drug discovery for this neglected disease.
This award will establish an exciting five-year multidisciplinary research programme at the forefront of research in the development of novel therapeutic agents for the treatment of Human African Trypanosomiasis (HAT) inspired by nature. The acetogenin family of natural products provide a molecular blueprint for the design of novel trypanocidal drugs. Such an approach to the discovery of HAT inhibitors has not been implemented despite the widespread use of Annonaceae plant family of trees, shrubs and vines in traditional medicine across sub-Saharan Africa. The challenge is to combine our expertise in organic synthesis and molecular parasitology within the Biomedical Science Research Complex to bring about a step change in drug discovery for this neglected disease.
